Trade this ETF at your broker
Fund size | EUR 6 m |
Total expense ratio | 0.60% p.a. |
Replication | Physical (Full replication) |
Legal structure | ETF |
Strategy risk | Long-only |
Fund currency | USD |
Currency risk | Currency unhedged |
Volatility 1 year (in EUR) | 18.08% |
Inception/ Listing Date | 27 May 2020 |
Distribution policy | Accumulating |
Distribution frequency | - |
Fund domicile | Ireland |
Fund Provider | First Trust |
Fund Structure | Open-ended Investment Company (OEIC) |
UCITS compliance | Yes |
Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
Investment Advisor | First Trust Advisors L.P. |
Custodian Bank | The Bank of New York Mellon SA/NV, Dublin Branch |
Revision Company | Deloitte |
Fiscal Year End | 31 December |
Swiss representative | Waystone Fund Services (Switzeland) SA |
Swiss paying agent | Banque Cantonale de Genève |
Tax data | Bundesanzeiger | |
Germany | 30% tax rebate | |
Switzerland | No ESTV Reporting | |
Austria | Tax Reporting Fund | |
UK | UK Reporting |
Indextype | Total return index |
Swap counterparty | - |
Collateral manager | |
Securities lending | No |
Securities lending counterparty |
NEUROCRINE BIOSCIENCES INC | 3.50% |
UNITED THERAPEUTICS CORP | 3.44% |
ALNYLAM PHARMACEUTICALS ORD | 0.00% |
GILEAD SCIENCES INC | 0.00% |
REGENERON PHARMACEUTICALS INC | 0.00% |
GRIFOLS S.A. ADR | 0.00% |
INCYTE CORP | 0.00% |
VERTEX PHARMACEUTICALS ORD | 0.00% |
METTLER TOLEDO INTL. INC | 0.00% |
ARGENX SP ADR | 0.00% |
United States | 79.55% |
Germany | 3.58% |
Netherlands | 3.47% |
Ireland | 3.12% |
Health Care | 89.72% |
Other | 10.28% |
YTD | -6.62% |
1 month | +4.30% |
3 months | -4.84% |
6 months | -8.43% |
1 year | -7.14% |
3 years | -0.30% |
5 years | - |
Since inception (MAX) | -9.14% |
2022 | +1.20% |
2021 | +4.30% |
2020 | - |
2019 | - |
Volatility 1 year | 18.08% |
Volatility 3 years | 22.77% |
Volatility 5 years | - |
Return per risk 1 year | -0.40 |
Return per risk 3 years | 0.00 |
Return per risk 5 years | - |
Maximum drawdown 1 year | -18.48% |
Maximum drawdown 3 years | -23.34% |
Maximum drawdown 5 years | - |
Maximum drawdown since inception | -25.05% |
Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
---|---|---|---|---|---|
Borsa Italiana | EUR | FBT | FBT IM FBTINAV | FBT.MI | |
London Stock Exchange | GBX | FBT | FBT LN FBTINAV | ||
London Stock Exchange | GBP | - | FBT LN | ||
London Stock Exchange | USD | FBTU | FBTU LN FBTINAV |
Fund name | Fund Size in m € (AuM) | TER in % p.a. | Distribution policy | Replication method |
---|---|---|---|---|
Invesco Nasdaq Biotech UCITS ETF | 474 | 0.40% p.a. | Accumulating | Swap-based |
iShares Nasdaq US Biotechnology UCITS ETF | 369 | 0.35% p.a. | Accumulating | Sampling |
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 36 | 0.35% p.a. | Distributing | Sampling |